PROTAGENIC THERAPUTCS WTS (PTIXW) Financials
Newest figures come from the 10-K for Q4 FY2025, filed Mar 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PTIXW SEC filings page.
PROTAGENIC THERAPUTCS WTS (PTIXW) reported $0 in revenue for fiscal year 2024. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
PROTAGENIC THERAPUTCS WTS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
PROTAGENIC THERAPUTCS WTS passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
PROTAGENIC THERAPUTCS WTS reported a net loss of $5.5M while operations used $4.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
PROTAGENIC THERAPUTCS WTS's EBITDA was -$913K in Q4 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 127.3% from the same quarter a year earlier. Against the prior quarter it is up 17.1%.
PROTAGENIC THERAPUTCS WTS reported $2.2M in net income in Q4 2025. This represents an increase of 360.0% from the same quarter a year earlier. Against the prior quarter it is up 354.3%.
PROTAGENIC THERAPUTCS WTS earned $1.14 per diluted share (EPS) in Q4 2025. Against the prior quarter it is up 342.6%.
Not reported for Q4 2025.
Cash & Balance Sheet
PROTAGENIC THERAPUTCS WTS held $2.2M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
PROTAGENIC THERAPUTCS WTS invested $154K in research and development in Q4 2025. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 43.7%.
Not reported for Q4 2025.
Not reported for Q4 2025.
PTIXW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-K | Q2'25 | Q1'25 | Q4'2410-K | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0 | $0 | N/A | $0 | $0 | $0 |
| R&D Expenses | $154K+14.3% | $273K+1510.6% | $394K+1959.6% | N/A | $135K | $17K-98.5% | $19K-97.1% | $1.5M+319.7% |
| SG&A Expenses | $155K+211.5% | $160K+626.0% | $175K+637.9% | N/A | $50K | $22K-92.8% | $24K-92.3% | $278K-29.0% |
| Operating Income | -$925K-130.5% | -$1.1M-213.4% | -$2.3M-628.5% | N/A | -$401K | -$355K+75.2% | -$322K+71.9% | -$1.7M-135.1% |
| EBITDA | -$913K-127.3% | -$1.1M-209.9% | -$2.3M-654.0% | N/A | -$401K | -$355K+75.2% | -$309K+73.0% | -$1.7M-133.5% |
| Interest Expense | $24K+105.3% | $34K+114.4% | -$239K | N/A | -$449K | -$239K-847.0% | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | -$3K | $3K | N/A |
| Net Income | $2.2M+360.0% | -$869K-49.3% | -$5.1M-1459.3% | N/A | -$850K | -$582K+58.3% | -$324K+73.2% | -$1.7M-140.1% |
| EPS (Basic) | $1.14+812.5% | -$0.47-327.3% | -$1.37-2183.3% | -$2.75+49.4% | -$0.16 | -$0.11+65.6% | -$0.06+78.6% | -$5.44-3100.0% |
| EPS (Diluted) | $1.14 | -$0.47 | -$1.37 | -$2.75+49.4% | -$0.16 | -$0.11+65.6% | -$0.06+78.6% | -$5.44 |
| Diluted Shares (Avg) | 2M | 2M | 4M | 523,185+65.1% | 5M | 5M+24.6% | 5M+24.6% | 316,804 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
PTIXW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-K | Q2'25 | Q1'25 | Q4'2410-K | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.4M+126.5% | $5.0M+231.7% | $6.5M+342.3% | $89K-96.5% | $2.0M-54.8% | $1.5M-72.2% | $1.5M-78.8% | $2.6M-66.4% |
| Current Assets | $2.3M+22.1% | $2.9M+100.9% | $4.3M+216.4% | $89K-96.4% | $1.9M-55.2% | $1.4M-73.5% | $1.4M-80.2% | $2.5M-67.8% |
| Cash & Equivalents | $2.2M+2680.8% | $2.7M+3713.2% | $4.1M+474.0% | $15K+794.2% | $80K-93.8% | $71K-53.4% | $714K+225.2% | $2K-98.8% |
| Inventory | $1K | $1K | $1K | $1K | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.8M+29.4% | $9.7M+143.9% | $10.5M+224.9% | $5.0M+15.4% | $5.3M+704.9% | $4.0M+210.8% | $3.2M+113.9% | $4.4M+248.9% |
| Current Liabilities | $6.8M+623.8% | $9.7M+1129.3% | $10.5M+1451.0% | $5.0M+1030.3% | $943K+43.9% | $789K-38.3% | $675K-55.2% | $446K-64.4% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $4.3M | $3.2M | $2.5M | $3.9M |
| Total Equity | -$2.4M+27.9% | -$4.7M-90.3% | -$4.0M-126.7% | -$5.0M-176.8% | -$3.3M-190.5% | -$2.5M-159.5% | -$1.8M-132.4% | -$1.8M-127.9% |
| Retained Earnings | -$9.1M+74.9% | -$11.3M+67.4% | -$10.5M+69.3% | -$5.4M+83.4% | -$36.3M-18.0% | -$34.7M-19.4% | -$34.1M-23.1% | -$32.5M-22.7% |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
PTIXW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-K | Q2'25 | Q1'25 | Q4'2410-K | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$510K+37.8% | -$1.4M-651.6% | -$1.2M-373.7% | N/A | -$820K+28.4% | -$186K+71.7% | -$246K+83.9% | -$1.7M-346.2% |
| Depreciation & Amortization | $13K | $13K | $13K0.0% | $13K0.0% | $0 | $0-100.0% | $13K+13714.3% | $13K+13868.9% |
| Stock-Based Compensation | N/A | N/A | $125K | $236K+45.8% | N/A | N/A | N/A | $162K-2.9% |
| Investing Cash Flow | $0 | $0 | $943K-41.1% | N/A | $0-100.0% | $0-100.0% | $1.6M-0.7% | $1.2M+308.2% |
| Financing Cash Flow | -$2-100.0% | -$15K-104.9% | $4.4M+359.5% | $103K | $1.6M | $317K | $963K | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
PTIXW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-K | Q2'25 | Q1'25 | Q4'2410-K | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Assets | 49.9%+93.4pp | -17.4%+21.2pp | -78.0%-55.8pp | N/A | -43.5% | -38.6%-12.9pp | -22.1%-4.6pp | -66.9%-57.5pp |
| Current Ratio | 0.34-1.7x | 0.29-1.5x | 0.41-1.6x | 0.02-5.5x | 2.00-4.4x | 1.80-2.4x | 2.03-2.6x | 5.53-0.6x |
| Asset Turnover | N/A | N/A | 0.000.0x | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$3.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PROTAGENIC THERAPUTCS WTS PTIXW | FY2024 | $0 | -$5.5M | N/A | N/A | — |
| Aspire-Lakewood Holdings, Inc. Warrant ASBPW | FY2025 | $6K | N/A | N/A | N/A | — |
| BriaCell Therapeutics Corp. Warrant BCTXW | FY2025 | N/A | -$26.3M | N/A | N/A | — |
| BriaCell Therapeutics Corp. Warrant BCTXZ | FY2025 | N/A | -$26.3M | N/A | N/A | — |
Where PROTAGENIC THERAPUTCS WTS Ranks
Frequently Asked Questions
What is PROTAGENIC THERAPUTCS WTS's annual revenue?
PROTAGENIC THERAPUTCS WTS (PTIXW) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is PROTAGENIC THERAPUTCS WTS profitable?
No, PROTAGENIC THERAPUTCS WTS (PTIXW) reported a net income of -$5.5M in fiscal year 2024.
What is PROTAGENIC THERAPUTCS WTS's EBITDA?
PROTAGENIC THERAPUTCS WTS (PTIXW) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is PROTAGENIC THERAPUTCS WTS's operating cash flow?
PROTAGENIC THERAPUTCS WTS (PTIXW) recorded an outflow of $4.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are PROTAGENIC THERAPUTCS WTS's total assets?
PROTAGENIC THERAPUTCS WTS (PTIXW) had $2.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does PROTAGENIC THERAPUTCS WTS spend on research and development?
PROTAGENIC THERAPUTCS WTS (PTIXW) invested $3.8M in research and development during fiscal year 2024.
What is PROTAGENIC THERAPUTCS WTS's current ratio?
PROTAGENIC THERAPUTCS WTS (PTIXW) had a current ratio of 2.00 as of fiscal year 2024, which is generally considered healthy.
What is PROTAGENIC THERAPUTCS WTS's return on assets (ROA)?
PROTAGENIC THERAPUTCS WTS (PTIXW) had a return on assets of -282.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is PROTAGENIC THERAPUTCS WTS's debt-to-equity ratio negative or not reported?
PROTAGENIC THERAPUTCS WTS (PTIXW) has negative shareholder equity of -$3.3M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is PROTAGENIC THERAPUTCS WTS's Piotroski F-Score?
PROTAGENIC THERAPUTCS WTS (PTIXW) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PROTAGENIC THERAPUTCS WTS's earnings high quality?
PROTAGENIC THERAPUTCS WTS (PTIXW) reported a net loss of $5.5M while operations used $4.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.